BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

654 related articles for article (PubMed ID: 33397677)

  • 1. Stereotypic neutralizing V
    Kim SI; Noh J; Kim S; Choi Y; Yoo DK; Lee Y; Lee H; Jung J; Kang CK; Song KH; Choe PG; Kim HB; Kim ES; Kim NJ; Seong MW; Park WB; Oh MD; Kwon S; Chung J
    Sci Transl Med; 2021 Jan; 13(578):. PubMed ID: 33397677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.
    Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H
    Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes.
    Voss WN; Hou YJ; Johnson NV; Delidakis G; Kim JE; Javanmardi K; Horton AP; Bartzoka F; Paresi CJ; Tanno Y; Chou CW; Abbasi SA; Pickens W; George K; Boutz DR; Towers DM; McDaniel JR; Billick D; Goike J; Rowe L; Batra D; Pohl J; Lee J; Gangappa S; Sambhara S; Gadush M; Wang N; Person MD; Iverson BL; Gollihar JD; Dye JM; Herbert AS; Finkelstein IJ; Baric RS; McLellan JS; Georgiou G; Lavinder JJ; Ippolito GC
    Science; 2021 Jun; 372(6546):1108-1112. PubMed ID: 33947773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses.
    Banach BB; Cerutti G; Fahad AS; Shen CH; Oliveira De Souza M; Katsamba PS; Tsybovsky Y; Wang P; Nair MS; Huang Y; Francino-Urdániz IM; Steiner PJ; Gutiérrez-González M; Liu L; López Acevedo SN; Nazzari AF; Wolfe JR; Luo Y; Olia AS; Teng IT; Yu J; Zhou T; Reddem ER; Bimela J; Pan X; Madan B; Laflin AD; Nimrania R; Yuen KY; Whitehead TA; Ho DD; Kwong PD; Shapiro L; DeKosky BJ
    Cell Rep; 2021 Oct; 37(1):109771. PubMed ID: 34587480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
    Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
    Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization.
    Peterhoff D; Glück V; Vogel M; Schuster P; Schütz A; Neubert P; Albert V; Frisch S; Kiessling M; Pervan P; Werner M; Ritter N; Babl L; Deichner M; Hanses F; Lubnow M; Müller T; Lunz D; Hitzenbichler F; Audebert F; Hähnel V; Offner R; Müller M; Schmid S; Burkhardt R; Glück T; Koller M; Niller HH; Graf B; Salzberger B; Wenzel JJ; Jantsch J; Gessner A; Schmidt B; Wagner R
    Infection; 2021 Feb; 49(1):75-82. PubMed ID: 32827125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.
    Huynh A; Arnold DM; Smith JW; Moore JC; Zhang A; Chagla Z; Harvey BJ; Stacey HD; Ang JC; Clare R; Ivetic N; Chetty VT; Bowdish DME; Miller MS; Kelton JG; Nazy I
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33923828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain.
    Wu NC; Yuan M; Liu H; Lee CD; Zhu X; Bangaru S; Torres JL; Caniels TG; Brouwer PJM; van Gils MJ; Sanders RW; Ward AB; Wilson IA
    Cell Rep; 2020 Oct; 33(3):108274. PubMed ID: 33027617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
    Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
    Front Immunol; 2021; 12():793953. PubMed ID: 34899762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
    Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
    Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals.
    Yoshida S; Ono C; Hayashi H; Fukumoto S; Shiraishi S; Tomono K; Arase H; Matsuura Y; Nakagami H
    Sci Rep; 2021 Mar; 11(1):5934. PubMed ID: 33723294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of antibody immunity to SARS-CoV-2.
    Gaebler C; Wang Z; Lorenzi JCC; Muecksch F; Finkin S; Tokuyama M; Cho A; Jankovic M; Schaefer-Babajew D; Oliveira TY; Cipolla M; Viant C; Barnes CO; Bram Y; Breton G; Hägglöf T; Mendoza P; Hurley A; Turroja M; Gordon K; Millard KG; Ramos V; Schmidt F; Weisblum Y; Jha D; Tankelevich M; Martinez-Delgado G; Yee J; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Robbiani DF; Zhao Z; Gazumyan A; Schwartz RE; Hatziioannou T; Bjorkman PJ; Mehandru S; Bieniasz PD; Caskey M; Nussenzweig MC
    Nature; 2021 Mar; 591(7851):639-644. PubMed ID: 33461210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain.
    Huang PH; Tsai HH; Liao BH; Lin YL; Jan JT; Tao MH; Chou YC; Hu CJ; Chen HW
    Hum Vaccin Immunother; 2021 Mar; 17(3):654-655. PubMed ID: 32991231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2.
    Lim SA; Gramespacher JA; Pance K; Rettko NJ; Solomon P; Jin J; Lui I; Elledge SK; Liu J; Bracken CJ; Simmons G; Zhou XX; Leung KK; Wells JA
    MAbs; 2021; 13(1):1893426. PubMed ID: 33666135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
    Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
    Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples.
    Mazzini L; Martinuzzi D; Hyseni I; Benincasa L; Molesti E; Casa E; Lapini G; Piu P; Trombetta CM; Marchi S; Razzano I; Manenti A; Montomoli E
    J Immunol Methods; 2021 Feb; 489():112937. PubMed ID: 33253698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.